Anuh Pharma Limited has informed the Exchange about Investor Presentation
ANUHPHR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Anuh Pharma shared its Q3 FY26 investor presentation highlighting strong sequential performance. Q3 revenue rose to ₹201 Cr from ₹186 Cr in Q2, while EBITDA surged 62.6% QoQ to ₹20.91 Cr with margin expanding to 10.60% (from 6.92%). 9M FY26 revenue grew 22.6% YoY to ₹578.02 Cr, though 9M EBITDA and PAT were down YoY (₹47.45 Cr and ₹29.36 Cr respectively) due to margin pressure in earlier quarters. The company successfully cleared a USFDA inspection in February 2026 with zero Form 483 observations, reinforcing its regulatory standing. Management reiterated its 15-16% annual growth target and indicated that the order book is healthy, with improving pricing in key molecules expected to support margin recovery going forward.
Sharp Q3 margin expansion, zero-observation USFDA clearance, and a reaffirmed 15-16% annual growth target are positive signals for shareholders. However, the YoY decline in 9M profits and the modest market cap of ₹819 Cr mean investors should watch for sustained margin recovery in the coming quarters to validate the upbeat guidance.